Lilly’s $7.8B Centessa Bet Signals a New M&A Playbook: Buy the Mechanism, Not the Molecule
Lilly's $7.8B Centessa acquisition, approved by UK High Court on June 22, reveals Big Pharma's new M&A logic: own...
Biogen’s Immunology Buying Spree Reveals a Strategy the Neurology Playbook Can No Longer Support
Biogen's $1B RayThera deal is its second major immunology acquisition in two years. A pipeline pivot this deliberate signals...
Tzield’s Stage 3 Approval Signals the End of Insulin’s Monopoly on Type 1 Diabetes
Sanofi's Tzield just won FDA approval for stage 3 T1D, threatening insulin's 68% grip on a $28.6B market and...
The Biased GLP-1 Signal: Ecnoglutide’s 35% Edge Over Semaglutide Is the Opening Shot in Obesity’s Next Competitive War
Sciwind's ecnoglutide beat semaglutide by 35% on weight loss in a head-to-head trial—and it signals a coming wave of...
J&J’s Nipocalimab Data Signals the FcRn Gold Rush Has a Real Leader
J&J's nipocalimab cut SLE disease activity in Phase 2 JASMINE—and with Phase 3 already recruiting, FcRn blockade is becoming...
The China Oncology Pipeline Is Going Global — And Pfizer Just Fired the Starting Gun
Pfizer's deal with Innovent Biologics joins a pattern of Western pharma betting on Chinese oncology pipelines to fill post-LOE...
The Pricing Policy Mirage: Three Signals That Washington’s Drug Cost Crusade Is Reshaping Pharma Strategy Without Fixing Prices
Trump's executive orders and IRA negotiations promise relief, but branded drug prices rose 4.5% in 2024 and U.S. drugs...
The Junk-to-Grade Playbook: Why Teva’s Upgrade Is a Signal, Not a Story
Teva's BBB- upgrade from Fitch on May 18 signals a new M&A-ready posture—and reveals a playbook other over-leveraged pharma...
The GLP-1 Wars Are Over — The Incretin Platform Wars Have Begun
Orforglipron's 72-week Phase 3 data, SURMOUNT-5's head-to-head verdict, and Roche's oral small molecule push signal a $87B market restructuring...
The FDA Just Validated a $1.6 Billion Platform — and the Real Winner Isn’t Pfizer
FDA's May 2026 approval of Veppanu, the first PROTAC drug, validates targeted protein degradation as a platform — and...